Author

M. Yarchoan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Approach:deep learning· 2 Research Focus:differential expression· 2 Assay:imaging· 2

Frequent Co-Authors

E. J. Fertig· 4 shared E. M. Jaffee· 3 shared L. Danilova· 3 shared L. T. Kagohara· 3 shared Q. Zhu· 3 shared W. J. Ho· 3 shared A. Deshpande· 2 shared A. Hernandez· 2 shared

Activity by Year

2023-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

E. J. Fertig

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Liver fibrosis uncouples tumor control from survival after multikinase inhibitor immunotherapy in hepatocellular carcinoma

S. Morita, T. Ando, H. Kikuchi, A. Morita, T. Kobayashi, G. Birch, R. Tanaka, A. Matsui, Z. Ruan, P. Huang, Y. Cho, A. Hernandez, J. W. Lee, E. M. Coyne, S. M. Shin, , D. G. Duda

Liver fibrosis limits the survival benefit of multikinase inhibitor immunotherapy in hepatocellular carcinoma by promoting innate immune-mediated hepatotoxicity despite preserved tumor control.

bioRxiv · Oct 20, 2023 · PreprintCancer Biology

Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade

D. H. Shu, W. J. Ho, L. T. Kagohara, A. Girgis, S. M. Shin, L. Danilova, J. W. Lee, D. N. Sidiropoulos, S. Mitchell, K. Munjal, K. Howe, K. J. Bendinelli, H. Qi, G. Mo, J. Montagne, , M. Yarchoan

This study examines TLS in HCC treated with neoadjuvant immunotherapy, finding TLS correlate with better outcomes and show distinct morphological and functional features in tumor regression.

bioRxiv · Oct 16, 2023 · PreprintImmunology

Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial

S. Zhang, A. Deshpande, B. K. Verma, H. Wang, H. Mi, L. Yuan, W. J. Ho, E. M. Jaffee, Q. Zhu, R. A. Anders, M. Yarchoan, L. T. Kagohara, E. J. Fertig, A. S. Popel

The paper develops a spatial quantitative systems pharmacology model for virtual clinical trials in HCC, validated with spatial multi-omics data from a neoadjuvant immunotherapy trial.

bioRxiv · Aug 11, 2023 · PreprintBioengineering

SpliceMutr enables pan-cancer analysis of splicing-derived neoantigen burden in tumors

T. Palmer, M. D. Kessler, X. M. Shao, A. Balan, M. Yarchoan, N. Zaidi, T. Y. Lopez-Vidal, A. Saeed, J. Gore, N. Azad, E. Jaffee, A. V. Favorov, V. Anagnostou, R. Karchin, D. Gaykalova, , E. J. Fertig

SpliceMutr quantifies splicing-derived neoantigens across cancers, finding correlations with immune biomarkers and treatment response.

bioRxiv · May 26, 2023Cancer Biology

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

S. Zhang, L. Yuan, L. Danilova, G. Mo, Q. Zhu, A. Deshpande, A. T. F. Bell, J. Elisseeff, A. S. Popel, R. A. Anders, E. M. Jaffee, M. Yarchoan, E. J. Fertig, L. T. Kagohara

This study uses spatial transcriptomics to analyze HCC tumors treated with cabozantinib and nivolumab, identifying distinct immune and fibrotic mechanisms linked to response and recurrence.

bioRxiv · Jan 10, 2023Cancer Biology